Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
NovMetaPharma Co., Ltd. has 4 pending office actions in Biotechnology & Pharmaceuticals. The matters are distributed across 4 examiners and 4 art units, creating separate examination paths without shared examiner or art-unit coverage.
KRINOS, EMILY LYNN is the busiest examiner, with 1 pending matter. Counsel should use application-specific prosecution plans while maintaining consistent scientific positions across the docket.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (25%) |
| Double-patenting + other | 1 (25%) |
| Multi-statute (no §101) | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KRINOS, EMILY LYNN | 1 | — | — |
| HOU, FRANK S | 1 | 67.8% | +36.7% |
| SIMMONS, CHRIS E | 1 | 34.2% | +19.6% |
| MOSELEY II, NELSON B | 1 | 67.9% | +41.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19107159 | USE OF COMPOSITION CONTAINING ZINC SALT AND CYCLO-HISPRO FOR PREVENTION, ALLEVIATION OR TREATMENT OF RESPIRATORY DISEASE | KRINOS, EMILY LYNN | — |
| 18204520 | COMPOSITION AND METHOD FOR TREATING CANCER | MOSELEY II, NELSON B | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18712003 | PROCESS FOR PREPARING ARYL ETHENE COMPOUND | HOU, FRANK S | — |
| 18385686 | METHOD FOR TREATMENT OF CYTOKINE RELEASE SYNDROME | SIMMONS, CHRIS E | — |
| 18204520 | COMPOSITION AND METHOD FOR TREATING CANCER | MOSELEY II, NELSON B | — |
| Art Unit | Apps |
|---|---|
| 1614 | 1 |
| 1692 | 1 |
| 1622 | 1 |
| 1642 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19107159 | USE OF COMPOSITION CONTAINING ZINC SALT AND CYCLO-HISPRO FOR PREVENTION, ALLEVIATION OR TREATMENT OF RESPIRATORY DISEASE | KRINOS, EMILY LYNN | 1614 | §102§112 | Non-Final OA | — | Pending | Feb 27, 2025 |
| 18712003 | PROCESS FOR PREPARING ARYL ETHENE COMPOUND | HOU, FRANK S | 1692 | §102 | Non-Final OA | — | Pending | May 21, 2024 |
| 18385686 | METHOD FOR TREATMENT OF CYTOKINE RELEASE SYNDROME | SIMMONS, CHRIS E | 1622 | §102§112DP | Non-Final OA | — | Pending | Oct 31, 2023 |
| 18204520 | COMPOSITION AND METHOD FOR TREATING CANCER | MOSELEY II, NELSON B | 1642 | §103§112 | Non-Final OA | — | Pending | Jun 01, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNovMetaPharma Co., Ltd. has 4 pending office actions as of October 2026, spread across 4 art units and 4 examiners.
Emily Lynn Krinos has the most, with 1 of NovMetaPharma Co., Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
